These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34016618)

  • 21. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
    Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM
    Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Buse JB; Wexler DJ; Tsapas A; Rossing P; Mingrone G; Mathieu C; D'Alessio DA; Davies MJ
    Diabetologia; 2020 Feb; 63(2):221-228. PubMed ID: 31853556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Patorno E; Htoo PT; Glynn RJ; Schneeweiss S; Wexler DJ; Pawar A; Bessette LG; Chin K; Everett BM; Kim SC
    Ann Intern Med; 2021 Nov; 174(11):1528-1541. PubMed ID: 34570599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.
    Li S; Vandvik PO; Lytvyn L; Guyatt GH; Palmer SC; Rodriguez-Gutierrez R; Foroutan F; Agoritsas T; Siemieniuk RAC; Walsh M; Frere L; Tunnicliffe DJ; Nagler EV; Manja V; Åsvold BO; Jha V; Vermandere M; Gariani K; Zhao Q; Ren Y; Cartwright EJ; Gee P; Wickes A; Ferns L; Wright R; Li L; Hao Q; Mustafa RA
    BMJ; 2021 May; 373():n1091. PubMed ID: 33975892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
    D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
    Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
    Patorno E; Pawar A; Bessette LG; Kim DH; Dave C; Glynn RJ; Munshi MN; Schneeweiss S; Wexler DJ; Kim SC
    Diabetes Care; 2021 Mar; 44(3):826-835. PubMed ID: 33495295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes.
    Luo J; Gabriel N; Korytkowski M; Hernandez I; Gellad WF
    Diabetes Res Clin Pract; 2022 May; 187():109855. PubMed ID: 35346753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials: Implications for practice.
    Battise DM; Olin JL
    J Am Assoc Nurse Pract; 2021 Mar; 33(12):1139-1147. PubMed ID: 33105320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
    Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
    Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure.
    Cromer SJ; Lauffenburger JC; Levin R; Patorno E
    Diabetes Care; 2023 Jan; 46(1):65-74. PubMed ID: 36383481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Yan Y; Al-Aly Z
    Diabetes Care; 2020 Nov; 43(11):2859-2869. PubMed ID: 32938746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
    Foer D; Beeler PE; Cui J; Karlson EW; Bates DW; Cahill KN
    Am J Respir Crit Care Med; 2021 Apr; 203(7):831-840. PubMed ID: 33052715
    [No Abstract]   [Full Text] [Related]  

  • 37. [Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes].
    Scheen AJ
    Rev Med Suisse; 2019 Aug; 15(659):1436-1441. PubMed ID: 31436058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
    Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
    JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.
    Dave CV; Schneeweiss S; Wexler DJ; Brill G; Patorno E
    Diabetes Care; 2020 Apr; 43(4):921-924. PubMed ID: 32041899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [SGLT2 inhibitor or GLP-1 receptor agonist in a type 2 diabetic patient with cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2018 Aug; 14(615):1460-1465. PubMed ID: 30136462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.